C4 Therapeutics Inc — Quarterly Cash Flow (NASDAQ:CCCC) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Total assets 376.06 M349.6 M319.52 M296.53 M265.49 M359.07 M Total liabilities 133.4 M133.62 M124.38 M122.46 M111.08 M102.49 M Total equity 242.66 M215.99 M195.14 M174.06 M154.41 M256.59 M Total liabilities & shareholders' equities 376.06 M349.6 M319.52 M296.53 M265.49 M359.07 M Total debt —————— Net debt ——————

Haberler

Barclays raises C4 Therapeutics stock price target on trial progress

TD Cowen reiterates Buy rating on C4 Therapeutics stock

C4 earnings beat by $0.11, revenue topped estimates

Brookline Capital raises C4 Therapeutics stock price target on trial progress

C4 Therapeutics doses first patient in phase 2 myeloma trial

C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock

C4 Therapeutics to advance cemsidomide trials for multiple myeloma

C4 Therapeutics stock initiated with Buy rating at TD Cowen

This Cloudflare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - BlackLine (NASDAQ:BL), C4 Therapeutics (NASDAQ:CCCC)

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

C4 earnings missed by $0.03, revenue topped estimates

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates